SG Americas Securities LLC Buys New Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

SG Americas Securities LLC purchased a new position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,308 shares of the company’s stock, valued at approximately $108,000.

Other large investors also recently bought and sold shares of the company. Soros Fund Management LLC acquired a new stake in shares of Neumora Therapeutics in the third quarter worth $141,000. Legal & General Group Plc purchased a new position in shares of Neumora Therapeutics during the 3rd quarter valued at about $140,000. Citigroup Inc. acquired a new position in shares of Neumora Therapeutics in the 3rd quarter valued at about $203,000. Royal Bank of Canada acquired a new stake in Neumora Therapeutics during the third quarter worth about $283,000. Finally, Qube Research & Technologies Ltd purchased a new position in Neumora Therapeutics during the third quarter valued at approximately $302,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Stock Down 3.5 %

NMRA opened at $10.18 on Friday. The firm’s fifty day simple moving average is $15.52 and its two-hundred day simple moving average is $14.14. Neumora Therapeutics, Inc. has a 52-week low of $9.35 and a 52-week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.05. Equities research analysts expect that Neumora Therapeutics, Inc. will post -1.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on NMRA shares. JPMorgan Chase & Co. raised their price objective on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, March 18th. William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a report on Friday, April 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $31.00 target price on shares of Neumora Therapeutics in a research note on Thursday, March 28th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.57.

Neumora Therapeutics Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.